Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateMar 7, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financial-reporting

TL;DR

Foghorn Therapeutics filed a routine 8-K on March 7th, no major news.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on March 7, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD disclosures and file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the procedural reporting of these items.

Why It Matters

This 8-K filing serves as a standard disclosure for Foghorn Therapeutics, informing the public about their operational and financial reporting status.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • March 7, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing for Foghorn Therapeutics?

The primary purpose is to report on the company's results of operations and financial condition, provide Regulation FD disclosures, and file financial statements and exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is March 7, 2024.

What is Foghorn Therapeutics' state of incorporation?

Foghorn Therapeutics Inc. is incorporated in Delaware.

What is the business address of Foghorn Therapeutics?

The business address is 500 Technology Square, Suite 700, Cambridge, MA 02139.

What standard industrial classification is Foghorn Therapeutics listed under?

Foghorn Therapeutics Inc. is listed under the standard industrial classification of Pharmaceutical Preparations [2834].

Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-07 07:11:23

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 7, 2024, Foghorn Therapeutics Inc. (the "Company") issued a press release announcing certain of the Company's financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated March 7, 2024, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued on March 7 , 20 24 99.2 Investor Presentation dated March 7, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael LaCascia Michael J. LaCascia Chief Legal Officer Date: March 7, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.